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Abstract
Background: Tumor resistance to chemotherapy may be present at the beginning of treatment,
develop during treatment, or become apparent on re-treatment of the patient. The mechanisms
involved are usually inferred from experiments with cell lines, as studies in tumor-derived cells are
difficult. Studies of human tumors show that cells adapt to chemotherapy, but it has been largely
assumed that clonal selection leads to the resistance of recurrent tumors.
Methods: Cells derived from 47 tumors of breast, ovarian, esophageal, and colorectal origin and
16 paired esophageal biopsies were exposed to anticancer agents (cisplatin; 5-fluorouracil;
epirubicin; doxorubicin; paclitaxel; irinotecan and topotecan) in short-term cell culture (6 days).
Real-time quantitative PCR was used to measure up- or down-regulation of 16 different resistance/
target genes, and when tissue was available, immunohistochemistry was used to assess the protein
levels.
Results: In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug
resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and
this was accompanied by increased expression of the MDR-1 encoded protein, P-gp. Following
exposure to doxorubicin in vitro, 13/14 breast carcinomas and 9/12 ovarian carcinomas showed >2-
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fold down-regulation of topoisomerase IIα (TOPOIIα). Exposure to topotecan in vitro, resulted in
>4-fold down-regulation of TOPOIIα in 6/7 colorectal tumors and 8/10 ovarian tumors.
Conclusion: This study suggests that up-regulation of resistance genes or down-regulation in
target genes may occur rapidly in human solid tumors, within days of the start of treatment, and
that similar changes are present in pre- and post-chemotherapy biopsy material. The molecular
processes used by each tumor appear to be linked to the drug used, but there is also heterogeneity
between individual tumors, even those with the same histological type, in the pattern and
magnitude of response to the same drugs. Adaptation to chemotherapy may explain why prediction
of resistance mechanisms is difficult on the basis of tumor type alone or individual markers, and
suggests that more complex predictive methods are required to improve the response rates to
chemotherapy.
Background
Tumor resistance to chemotherapy is a well-known clini-
cal phenomenon that is now yielding its secrets to investi-
gation at the molecular level in biopsy material. Studies in
cell lines do not always correlate well with results from
tumor tissue [1], which may consist largely of non-neo-
plastic cells that support and modify the biology of neo-
plastic cells. Thus it is important to validate the
mechanisms important in vitro with the situation in the
patient. Nevertheless, cell line studies and immunohisto-
chemical studies of tumors suggest that resistance is a
selective process: only those cells that survive a drug-
induced insult will re-grow.
We have previously shown development of such resist-
ance to combination chemotherapy in tumor-derived
cells from matched biopsies collected from breast cancer
patients before and after administration of doxorubicin-
containing chemotherapy [2]. In this study we show sim-
ilar results in patients with esophageal cancer from biop-
sies obtained prior to and several months after
chemotherapy. Two cycles of the combination of epiru-
bicin, cisplatin and 5-FU (ECF) are given to these patients
prior to resection, allowing studies to be performed with
paired samples before and after chemotherapy. We have
used real-time quantitative RT-PCR (qRT-PCR) and
immunohistochemistry (IHC) to assess targets known to
be of importance to resistance to these agents.
The mechanisms involved in resistance to chemotherapy
usually involve up-regulation of resistance mechanisms,
or down-regulation of target genes. Examples of the
former include drug efflux pump molecules such as multi-
drug resistance gene 1/P-glycoprotein (MDR1/P-gp),
while the latter include topoisomerases (TOPOs), targets
of drugs such as etoposide and doxorubicin. Many papers
attest to the importance of clonal selection in this process:
it is for instance possible to expose cell lines to low con-
centrations of drugs and, over time, to produce highly
resistant sub-clones [3]. However, there is another poten-
tial mechanism that does not require clonal selection:
cells may be able to adapt by regulation of expression of
resistance or target molecules individually if they survive
the initial exposure to the drug. This could be a more
rapid process and would require changes in molecular
expression, possibly due to epigenetic change, rather than
genetic mechanisms such as mutation [4]. As a result,
resistance may therefore arise rapidly following treatment
with chemotherapy.
Recent studies have shown that the expression of MDR1/
P-gp is up-regulated within hours of anti-cancer drug
treatment in vivo in patient samples [5-8], although this
effect was not observed in all patients. We therefore
wished to examine how quickly and in how many cases
these resistance molecules were up-regulated in tumor-
derived cells from several tumor types. We have used
selective short-term cell culture (6 days) to examine the
changes in expression that occur following exposure to
chemotherapy compared to medium-only control cells
from the same samples. Our short-term culture system
employs a serum-free medium and polypropylene 96 'U'
well microplates. This inhibits the proliferation and sur-
vival of normal cells and allows selective survival of a neo-
plastic cell population [9]. The short incubation period
also limits the possibility of selection of clones or sub-
populations in vitro. However, the presence of non-neo-
plastic cells for most of the incubation period allows the
interaction between stromal cells and neoplastic cells, a
factor that appears to be important to maintain the chem-
osensitivity profile [10].
Methods
Patients and tissue samples for in vitro studies
Tumor derived cells were obtained from 17 breast cancer
patients (16 primaries; 1 pre-treated with mitoxantrone
and paclitaxel), 13 ovarian cancer patients (all pre-treated
with a cisplatin-based regimen), 10 colorectal cancer
patients (all primaries) and 7 esophageal cancer patients
(3 untreated; 4 treated with ECF). Cells were grown for 6
days in serum-free medium with or without drugs, before
RNA extraction and further PCR analysis.BMC Cancer 2005, 5:78 http://www.biomedcentral.com/1471-2407/5/78
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Patients and tissue samples for in vivo study
Thirty-four esophageal adenocarcinoma biopsies, thirty-
two of which were paired samples were obtained from
patients (17M:1F; median age 57, range 42–81) before
and after administration of 2 cycles of ECF chemotherapy.
After enzymatic digestion, tumor derived cells were centri-
fuged over Ficoll (Sigma Chemical Co, Poole, UK, Cat.
No. 1077-1) to remove blood contaminating cells,
washed in PBS, and stored in RNA later (Ambion,
Huntingdon, UK) at -80°C until further molecular analy-
sis was performed. Tissue sections from these samples
were stained for GST-π, MRP1, P-gp and TS. All tumor
samples were removed as part of patient treatment, with
consent for tissue donation and local research ethics com-
mittee approval for use of the tissue surplus to diagnostic
requirements for cellular and molecular assays. Chemo-
sensitivity data were available for 9 patients with recurrent
ovarian cancer, before treatment and on relapse, though
in only one case was material available from both samples
for quantitative RT-PCR.
Drugs
Cisplatin, 5-fluorouracil (5-FU), epirubicin, doxorubicin,
irinotecan, paclitaxel (Taxol®) and topotecan (Hycamp-
tin®) were obtained from the pharmacy at Queen Alexan-
dra Hospital (Portsmouth, UK). Cisplatin, 5-FU,
irinotecan and paclitaxel were stored at room tempera-
ture, while all other drugs were stored at -20°C, as previ-
ously reported [11]. Test drug concentrations (TDC) were
10.0 µM for cisplatin, 345 µM for 5-FU, 148 µM for iri-
notecan, 15.9 µM for paclitaxel, 2.5 µM for doxorubicin,
0.862  µM for epirubicin, and 1.64 µM for topotecan.
Combinations were made up by adding two or three drugs
concurrently at their 200% TDC at the beginning of the
ATP-cell viability assay and diluted in a constant ratio:
sequential studies were not performed.
Short-term cell culture
Briefly, tumor tissue or fluid was taken by a histopatholo-
gist or surgeon under sterile conditions, and transported
to the laboratory in cell culture medium of Dulbecco's
modified Eagle's medium (DMEM; Sigma Cat No.
D5671) with antibiotics (100 U/ml penicillin and 100 µg/
ml streptomycin, Sigma, Cat No. P0781) at 4°C. Cells
were obtained from solid tumors by enzymatic dissocia-
tion, usually 0.75 mg/ml collagenase (Sigma Cat No. C-
8051) overnight. Viable tumor-derived cells were purified
by density centrifugation (Histopaque 1077-1, Sigma),
washed, counted and resuspended to 100,000 cells/ml in
case of effusions or 200,000 cells/ml for solid biopsies. In
the meantime 96-well polypropylene microplates (Corn-
ing-Costar, High Wycombe, UK; Cat No. 3790) were pre-
pared with each drug/combination at six doubling
dilutions in triplicate from 200% TDC to 6.25% TDC,
according to Andreotti et al. [9]. Approximately 10,000–
20,000 cells/well were added to the plates to a final vol-
ume of 200 µl/well. The plates were then incubated at
37°C in 5% CO2 for 6 days, after which the degree of cell
inhibition was assessed by measurement of the remaining
ATP in comparison with negative control (no drug, MO)
and positive control (maximum inhibitor, MI) rows of 12
wells each. Prior to cell lysis with an ATP-extracting rea-
gent, an aliquot of 150 µl of cell suspension were removed
from each well, centrifuged, washed with phosphate buff-
ered saline (PBS) and stored at -80°C in a GTIC-contain-
ing solution (lysis buffer RA1, Macherey-Nagel, Düren,
Germany; Cat. No.740961) until further molecular analy-
sis was carried out. The RNA was subsequently extracted
from aliquots that had been exposed to a drug concentra-
tion capable of inhibiting cell growth by 40–60%. ATP
was extracted from the remaining 50 µl cell suspension
and measured by light output in a microplate luminome-
ter (Berthold Diagnostic Systems GmbH, Pforzheim, Ger-
many) following addition of luciferin-luciferase.
RNA extraction
Cells obtained after enzymatic dissociation from endo-
scopic esophageal biopsies or short term cell culture were
either resuspended in RNA later (Ambion, Huntingdon,
UK; Cat No. 7020) or lysed with buffer RA1 and stored at
-80°C until RNA extraction. Total RNA was extracted from
at least 50,000 cells with a commercially available kit
(NucleoSpin®  RNA II mini, Macherey-Nagel; Cat No.
740955) according to the manufacturer's instructions.
The protocol included a DNase digestion step to prevent
carry-over of genomic DNA in further analysis.
qRT-PCR
A two-step protocol was employed. Firstly, total RNA was
reverse-transcribed using the Promega reverse transcrip-
tion system (Promega, Southampton, UK; Cat No.
A3500) including 8 µl RNA, 0.5 µg random primers, 20
units of recombinant RNasin® ribonuclease inhibitor and
15 units of reverse transcriptase AMV (Promega, Cat No.
M9004) to each 20 µl reaction. The resulting c-DNA was
amplified by qPCR on a Biorad iCycler instrument (Bio-
Rad Laboratories, Hemel Hampstead, UK). The constitu-
ents of each PCR reaction (25 µl) were 1 µl of cDNA (or
H2O), 200–500 nM of each primer (Table 1), 200 µM
each dATP, dCTP, dGTP, 400 µM dUTP, 3.0–5.0 mM
MgCl2, 0.125 units AMPErase® UNG, 0.625 units of Ampl-
iTaq Gold DNA polymerase and 1 × SYBR Green PCR
buffer (all reagents were from Applied Biosystems, War-
rington, UK). Product amplification was performed up to
45 PCR cycles, after uracil removal (2 min at 50°C) and
polymerase activation (10 min at 95°C). Each two-step
PCR cycle comprised denaturing (15 s at 95°C), anneal-
ing, and extending (1 min at 60°C). At the end of each run
a final melt curve cycle (cooling to 50°C and then increas-
ing stepwise 1°C to 95°C) was performed to exclude theBMC Cancer 2005, 5:78 http://www.biomedcentral.com/1471-2407/5/78
Page 4 of 16
(page number not for citation purposes)
presence of primer-dimer artefacts. At least 3 housekeep-
ing genes were used for each experiment chosen from the
following: glyceraldehyde-3 phosphate dehydrogenase
(GAPDH), hypoxanthine phosphoribosyltransferase 1
(HPRT1), human porphobilinogen deaminase (PBGD),
succinate dehydrogenase complex-subunit A (SDHA) and
TATA box binding protein (TBP). The internal reference
genes were selected due to their relative low abundance in
normal tissue [12]. The housekeeping genes were ampli-
fied parallel to the target genes in separate wells. When
possible, primer sequences (Table 1) were chosen to span
exon boundaries to the following targets: breast cancer
Table 1: List of primers for qRT-PCR. Sequence of primers (forward and reverse) used for qRT-PCR experiments. GenBank accession 
numbers for each gene are indicated in brackets. The primers were designed using an old version of the software Primer 3.0, available 
at the following website: http://www-genome.wi.mit.edu/cgi-bin/primer/primer3.cgi/
Name Sequence 5'-3' (forward and reverse primer) Product length Primer nM Mg2+ mM Reference
GAPDH* (NM_002046) GAA GGT GAA GGT CGG AGT C 226 200 4 -
GAA GAT GGT GAT GGG ATT TC 200
HPRT1* (NM_000194) TCA GGC AGT ATA ATC CAA AGA TGG T 84 400 4 [38]
AGT CTG GCT TAT ATC CAA CAC TTC G 400
PBGD* (NM_000190) CTG CAC GAT CCC GAG ACT CT 98 400 4 [39]
GCT GTA TGC ACG GCT ACT GG 400
SDHA* (NM_004168) TGG GAA CAA GAG GGC ATC TG 400 4 [12]
CCA CCA CTG CAT CAA ATT CAT G 400
TBP* (X54993) CAC GAA CCA CGG CAC TGA TT 89 400 4 [40]
TTT TCT TGC TGC CAG TCT GGA C 400
BCRP (AF098951) CAC AAC CAT TGC ATC TTG GC 74 400 4 [41]
GCT GCA AAG CCG TAA ATC CA 400
DPD (NM_000110) CCA AAG GCA GTA AAG CAG GAA 66 400 4 [42]
TCA CGA CTC CCC GTA TCG A 400
EGFR (NM_005228) TGG TCA AGT GCT GGA TGA TAG A 156 400 4 -
GGT AGA AGT TGG AGT CTG TAG GA 400
ERCC-1 (NM_001983) GGG AAT TTG GCG ACG TAA TTC 71 400 3 [43]
GCG GAG GCT GAG GAA CAG 400
GST-π (NM_000852) CGG AGA CCT CAC CCT GTA 169 400 5 -
CGC CTC ATA GTT GGT GTA GA 400
MDR1 (AF016535) TGG TTC AGG TGG CTC TGG AT 72 300 4 [44]
CTG TAG ACA AAC GAT GAG CTA TCA CA 300
MLH-1 (NM_000249) GGC ACA GCA TCA AAC CAA GT 147 400 4 -
GCA AGC ATG GCA AGG TCA A 400
MRP1 (L05628) CAA TGC TGT GAT GGC GAT G 70 400 4 [39]
GAT CCG ATT GTC TTT GCT CTT CA 400
MRP2 (NM_000392) TGC AGC CTC CAT AAC CAT GAG 80 400 3 [45]
GAT GCC TGC CAT TGG ACC TA 400
MT-II (NM_005953) GAT CCC AAC TGC TCC TGC 127 400 4 -
ACT TGG CAC AGC CCA CAG 400
MVP (NM_017458) CAG CTG GCC ATC GAG ATC A 68 400 4 [39]
TCC AGT CTC TGA GCC TCA TGC 400
TP (NM_001953) CCT TGG ATA AGC TGG AGT CT 107 400 4 -
CCT ACT CTG ACC CAC GAT AC 400
TS (NM_001071) CCA GAG ATC GGG AGA CAT GG 66 400 4 -
TAC GTG AGC AGG GCG TAG CT 400
TOPO I (J03250) CTC CAC AAC GAT TCC CAG AT 149 400 3 -
TTA TGT TCA CTG TTG CTA TGC TT 400
TOPO IIα (NM_001067) GTA ATT TTG ATG TCC CTC CAC GA 223 400 3 -
TCA AGG TCT GAC ACG ACA CTT 400
TOPO IIβ (NM_001068) GCA GCC GAA AGA CCT AAA TA 85 400 3 -
AAT CAT TAT TGT CAT CAT CAT CAT C 400
(N.B. Where primer sequences have been taken from references the PCR conditions have been further optimised compared to the original 
reference.)
* Housekeeping genes.BMC Cancer 2005, 5:78 http://www.biomedcentral.com/1471-2407/5/78
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resistance protein (BCRP), dihydropyrimidine dehydro-
genase (DPD), epidermal growth factor receptor (EGFR),
excision repair cross-complementing 1 (ERCC1) gene,
glutathione-S-transferase isoform π (GST-π), multi-drug
resistance gene 1 (MDR1), MLH1, multi-drug resistance
related protein 1 (MRP1), multi-drug resistance related
protein 2 (MRP2), metallothionein (MT), major vault
protein (MVP), thymidine phosphorylase (TP), thymi-
dylate synthase (TS), topoisomerase I (TOPO I), topoi-
somerase IIα and β (TOPO IIα and TOPO IIβ). Each
amplicon was amplified in a separate reaction to prevent
competition among multiple sets of primers. A positive
control (pooled c-DNA from a variety of human tumors,
including breast, ovarian, colorectal and esophageal carci-
noma) and negative controls with no template and RT-
negative as template were added in every experiment. All
assays were run in triplicate. Validation experiments were
run to show that the efficiencies of the target and reference
genes amplifications were approximately equal, and in
the range 95–105%. The PCR cycle number that generated
the first fluorescence signal above a threshold (threshold
cycle, Ct; 10 standard deviations above the mean fluores-
cence generated during the baseline cycles) was deter-
mined, and a comparative Ct method was then used to
measure relative gene expression [13]. The following for-
mula was used to calculate the relative amount of the tran-
script in the sample: 2-∆∆Ct, where ∆Ct is the difference in
Ct between the gene of interest and the mean of the at
least two reference genes, and ∆∆Ct = ∆Ct of drug non-
exposed cells – ∆Ct of drug-exposed cells, for the ex-vivo
experiments, or ∆∆Ct = ∆Ct of pre-chemotherapy sample
– ∆Ct of post-chemotherapy sample, for matched tumor
biopsies.
Immunohistochemistry
The monoclonal antibodies (Abs) for GST-π, MRP1, Pg-p,
and TP (Table 2) were detected using the Chemicon IHC
Select™ – Immuno Peroxidase secondary detection system
(Chemicon International, Chandlers Ford, Southampton,
UK, Cat# Det-HP1000) and stained with 3,3' diami-
nobenzidine (DAB; HD Supplies, Aylesbury, UK, Cat.
4170) on a Dako Autostainer instrument (Dako, Ely, UK).
Positive and negative controls were included with each
run. Volumes of 50 µl avidin/ml goat serum and 50 µl
biotin/ml primary Ab were used to block endogenous avi-
din binding. The slides were counterstained with Gills
Haematoxylin, dehydrated and cleared using the Leica© XL
slide staining machine and mounted in Styrolite® mount-
ing medium (BDH, Poole, Dorset, UK; Cat No. 361704Y).
Data analysis
The luminometer readings obtained from the ATP-TCA
were entered into an Excel 2000 spreadsheet (Microsoft)
which calculated the percentage of cell inhibition for each
drug concentration according to the previous published
formula: 1 - [(Test - MI)/(MO - MI)]*100 [9]. For each
drug-response curve, the 50% inhibitory concentration
(IC50) and the 90% inhibitory concentration (IC90) were
also calculated as previously described [14].
Assessment of slides was done using the H-score. Staining
intensity (none, 0 points; weak, 1 point; moderate, 2
points; strong, 3 points) and percentage of positive tumor
cells were multiplied to achieve a score between 0 and
300. A H-score of 100 or more was regarded as positive
and results less than 100 were regarded as negative. The
correlation coefficients were calculated by the method of
the least squares, and the correlation between the IC90
and IC50 values and immunohistochemistry indices was
assessed using univariate linear regression (Statsdirect,
Sale, UK).
Non-parametric statistical methods were used. The calcu-
lated and descriptive data were entered into an Access
2000 database (Microsoft) and analysed using a Wilcoxon
two-tailed paired rank sum test for paired data or the
Table 2: List of antibodies used for immunohistochemical studies.
Antibody Pre-Treatment Dilution Incubation Cat No. Source Control Tissue
Glutathione S-Transferase pi 
GST-π (polyclonal)
None 1:150 30 min RT PU249-UP BioGenex (Distributor: 
Menarini Diagnostics, 
Wokingham, UK)
Breast Ca
P-glycoprotein (MDR-1) 
(Clone JSB-1)
Pressure Cook 2 
min pH 6.0
1:100 Overnight 4°C NCL-JSB1 Novo Castra Newcastle-
upon-Tyne, UK
Kidney
Multidrug Resistant-Related 
Protein (MRP) (Clone 
MRPm6, specific for MRP-1)
Pressure Cook 2 
min pH 7.0
1:30 30 min RT MAB4122 Chemicon International 
Chandlers Ford, UK
Kidney
Thymidylate Synthase TS 
(Clone TS 106)
Pressure Cook 2 
min pH 6.0
1:20 30 min RT MS471P Neo Markers (Distributor: 
Lab Vision, Newmarket, UK)
Colon Ca
When sections required microwaving a Matsui MIIOM microwave was used at 800 W power. Pressure cooking was performed with a Tefal Clipso 
Pressure Cooker using 70 P power.BMC Cancer 2005, 5:78 http://www.biomedcentral.com/1471-2407/5/78
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Mann-Whitney U test for unpaired data, as appropriate
(Statsdirect). IC50 and IC90 values for each compound
were correlated to the relative mRNA levels of target genes
using Spearman's rank correlation coefficient and multi-
variate analysis. On statistical advice, we chose not to use
a Bonferroni's correction, but it should be noted that
some technically statistically significant results could have
arisen by chance.
Results
Chemotherapy-induced changes in mRNA levels in biopsy 
material
Figures 1a–e illustrate changes to IC50 µM values in pre-
and post chemotherapy ovarian tumor-derived cells tested
with a variety of chemotherapeutic agents. There is a gen-
eral increase in resistance to doxorubicin when anthracy-
cline-based regimens (mitoxantrone + paclitaxel or
liposomal doxorubicin) are administered to ovarian
cancer patients (Fig. 1a). We observed little cross-resist-
ance for mitoxantrone, topotecan, paclitaxel, and cispla-
tin following anthracycline-based chemotherapy (Fig.
1b–e), [15], although some patients do show alteration of
sensitivity to other agents. Similar changes can be seen in
breast cancer biopsies before and after administration of a
chemotherapy regimen [2]. The increase in resistance to
doxorubicin shown in Figure 1a was accompanied by
changes in drug resistance gene expression. Figure 1f high-
lights such up-regulation of MDR1 and breast cancer
resistance protein (BCRP) observed in ovarian-tumor
derived cells from a single patient.
Membrane proteins such as MDR1/P-gp, multi-drug
resistance protein 1 (MRP1) and major vault protein
(MVP) have been demonstrated to confer resistance to
epirubicin by pumping the cytotoxic drug out of cells [16].
Paired esophageal samples were obtained from the same
six patients both before and after chemotherapy; in all 6
biopsy pairs (Table 3), there was an increase of the mRNA
levels of MDR1 following ECF chemotherapy (Fig. 2a). In
a larger series of 20 esophageal samples (including those
that did not have a paired biopsy), divided in two groups
according to the patients' exposure to treatment, there was
a 5-fold increase in MDR1 expression in the post-chemo-
therapy group (median expression index 0.07 pre- and
0.37 post-chemotherapy, p < 0.0001, Mann-Whitney
non-parametric unpaired U test). The paired samples
from patients before and after ECF chemotherapy also
showed a trend towards increased expression of MRP1
and MVP (Table 3), with three tumors showing concomi-
tant up-regulation of both genes. Furthermore, the
increased expression of MRP1 paralleled that of glutath-
ione-S-transferase isoform π (GST-π) in 2 of these 3 sam-
ples, consistent with the mechanism of detoxification of
MRP1 that involves transport of glutathione-conjugated
molecules [17].
We then determined the relative mRNA levels of enzymes
that have previously been correlated with 5-FU sensitivity:
dihydropyrimidine dehydrogenase (DPD), thymidine
phosphorylase (TP) and thymidylate synthase (TS) [18].
No significant difference was found for these 3 genes
when we compared their expression pre- and post-chem-
otherapy in unpaired samples (Table 3). However, we
found a modest increase of TS expression in 5/6 paired
samples (Fig. 2b), 3 of which also showed a concomitant
decrease in TP levels. One sample showed a paradoxical
decrease in TS, indicating some heterogeneity. Although
the sample size is small, the trend of increased TS levels in
ECF exposed tumors is consistent with a number of previ-
ous reports that demonstrated an acute induction of TS
expression in cell lines, animal models and human
tumors following 5-FU treatment [18,19].
It should be noted that these qRT-PCR results were all
obtained from samples that included normal cells present
in the tumor as well as neoplastic cells, and could be
affected by changes in normal cells as well as malignant
cells.
Chemotherapy-induced changes in protein levels in biopsy 
material
IHC was performed on 16 paired esophageal biopsies:
qRT-PCR data were obtained for four of these pairs. Over-
all, we were able to confirm an increased expression of the
MDR-1 encoded protein, P-gp (Table 4), in 8/16 paired
tumor samples obtained from patients who had been
exposed to ECF chemotherapy. TS positivity (Table 4) was
found in 10/16 samples obtained before treatment and
10/16 post-chemotherapy specimens; in this instance the
modest induction of TS seen at the mRNA level did not
reflect an increase in protein level (data not shown). We
found GST-π (Table 4) positivity in 5/16 pre-chemother-
apy biopsies. In the post-chemotherapy specimens we
detected strong expression of GST-π in all but one of the
samples. In one case that had been negative at diagnosis
we measured a marginal increase of mRNA levels with
qRT-PCR. A total of 13/16 pre- and 12/16 post-chemo-
therapy biopsies were found to be positive for MRP1
(Table 4). Overall, these data show little correlation
between the mRNA and the degree of expression of pro-
tein levels determined by IHC. Confounding factors may
be the presence of non-cancerous cells as mentioned
above, but also the nature of IHC, which is at best a semi-
quantitative technique.
Changes in short-term cell culture
Of the 47 solid tumor samples studied in short-term cul-
tures, 7 were esophago-gastric, 17 were breast carcinomas,
13 were ovarian carcinomas and 10 were colorectal
tumors. A total of 93 experiments were performed, as inBMC Cancer 2005, 5:78 http://www.biomedcentral.com/1471-2407/5/78
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Changes due to chemotherapy in biopsies taken before and after chemotherapy Figure 1
Changes due to chemotherapy in biopsies taken before and after chemotherapy. Cytotoxicity of a) doxorubicin; b) mitox-
antrone; c) topotecan; d) paclitaxel and e) cisplatin (expressed as IC50 µM) in paired samples obtained from ovarian cancer 
patients before and after they were treated with an anthracycline containing regimen (paclitaxel+mitoxantrone n = 7; liposomal 
doxorubicin n = 2). Each line represents an individual patient. (f) Gene expression changes pre- and post-treatment (paclitaxel 
plus mitoxantrone chemotherapy) in one patient were analysed by qRT-PCR following in vitro exposure to doxorubicin.
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most cases the same sample was treated with 2 or more
drugs.
Doxorubicin effects in short-term cell culture
In the first instance, we decided to study the effects of
anthracycline exposure for 6 days on tumour-derived
cells. Our in vitro experiments showed a significant down-
regulation of TOPO IIα; its median levels decreased from
0.546 (range 0.005–1.782) to 0.017 (range 0.0004–
0.595) units in a group of 14 breast samples (p < 0.0001,
Wilcoxon matched pairs test) and from 1.491 (range
0.080–6.884) to 0.089 (range 0.003–3.605) units in the
ovarian cancer subgroup (p < 0.0015, Wilcoxon matched
pairs test). The down-regulation of TOPO IIα levels was
greater than 2-fold in 13/14 breast samples and in 9/12
ovarian samples (Fig. 3a). It has been suggested that can-
cer cells can concomitantly down-regulate TOPO IIα and
up-regulate TOPO I in response to treatment with
topoisomerase II inhibitors [20]. In our series we noted a
general trend of diminished levels of TOPO I, particularly
in the ovarian subgroup (Fig 3b). It is possible that doxo-
rubicin exposure resulted in quiescence of cells which
were not killed, and which would not therefore require
higher levels of TOPO I, or that doxorubicin may also
partly inhibit TOPO I, as suggested by a previous study
[21].
We observed a significant up-regulation of MRP-1 (p <
0.0001, Wilcoxon matched pairs test; Fig. 3c) and of MVP
(p < 0.0023, Wilcoxon; Table 5) in the breast cancer sub-
group. The same effect was not found in the ovarian
cancer group, in which the levels of MRP-1 and MVP
increased over 0.5 fold in only 4/12 and 3/12 samples,
respectively (Table 5). No significant changes were found
in the expression of MDR-1 and BCRP, although it should
be noted that there was substantial heterogeneity among
individual tumors (Table 5). For example, we measured a
greater than 2-fold increase of MDR-1 levels in 2/12 ovar-
ian samples (none of whom had received a MDR-1
pumped chemotherapeutic agent before), and a signifi-
cant up-regulation of BCRP in 3/12 ovarian samples.
Topoisomerase I inhibitors effects in short-term cell 
culture
Subsequently we looked at the effect of 2-camptothecin
derivatives, irinotecan and topotecan, on colorectal and
ovarian tumor cells, respectively (Table 6). As both
compounds act by TOPO I inhibition, we firstly measured
the levels of their target enzyme. We noted a trend towards
down-regulation of TOPO I in treated cells: exposure to
irinotecan decreased TOPO I levels >2-fold in 3/7 colorec-
tal tumors, while topotecan caused down-regulation in 4/
10 ovarian samples (Fig. 3d). The decrease of TOPO I was
accompanied by a concomitant reduction of TOPO IIα
expression, which was particularly pronounced (>4-fold)
in 6/7 colorectal tumors and 8/10 ovarian tumors (Fig.
3e).
No significant changes were observed in the expression of
the drug efflux molecules, MDR-1, BCRP and MRP-1
(Table 6), though, as in the case of doxorubicin, consider-
able heterogeneity was noted. We observed an increase of
BCRP levels after irinotecan or topotecan exposure in 2/7
colorectal samples and 3/9 ovarian samples.
Amongst the genes implicated in DNA repair (Table 6),
the modest down-regulation of MLH1 by topotecan expo-
sure was not found statistically significant, although it was
noted in 7/10 ovarian samples. Up-regulation of ERCC1
expression was found in all 10 ovarian cancer samples
exposed to topotecan (p < 0.002, Wilcoxon), and in all 7
colorectal specimens treated with irinotecan, although in
this group the increase was modest (p = 0.016, Wilcoxon).
Table 3: Relative expression of mRNA levels in esophageal samples obtained from patients before and after chemotherapy (median 
values). The last 2 columns on the right represent values for the 12 paired biopsies. The p values have been calculated using non 
parametric statistics, and in detail the Mann Whitney U test for unpaired samples, and the Wilcoxon matched pairs test for paired 
samples.
All esophageal samples Paired esophageal samples
Target gene Pre-chemo n = 13 Post-chemo n = 6 p Pre-chemo n = 6 Post-chemo n = 6 p
DPD 0.71 1.09 0.4117 0.68 1.09 0.3750
GST-π 4.39 0.88 0.1969 1.61 1.85 0.8438
MDR1 0.07 0.37 <0.0001 0.11 0.43 0.0313
MRP1 4.81 10.60 0.1624 4.58 10.77 0.4375
MT II 36.35 23.43 0.5846 12.49 24.12 0.8438
MVP 6.61 8.57 0.6544 6.39 9.11 0.5625
TP 4.21 2.58 0.2326 3.56 3.01 >0.999
TS 1.11 2.43 0.1851 1.27 2.27 0.4375BMC Cancer 2005, 5:78 http://www.biomedcentral.com/1471-2407/5/78
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Changes in relative gene expression in 6 paired esophageal tumor biopsies Figure 2
Changes in relative gene expression in 6 paired esophageal tumor biopsies. a) Changes in MDR1 relative gene expression and 
b) changes in TS relative gene expression. Each dot represents the relative mRNA level for an individual tumor, measured 
before and after ECF chemotherapy.
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Table 4: Median expression (range in brackets) of protein levels in paired esophageal samples (n = 16) obtained from patients before 
and after chemotherapy. Slides were assessed using the H-score. A H-score of 100 or more was regarded as positive and below 100 
was regarded as negative.
Antibody Pre-chemotherapy Post-chemotherapy
GST-π 35 (0–300) 200 (70–300)
P-gP 45 (0–300) 100 (0–300)
MRP 100 (0–200) 100 (10–200)
TS 120 (0–300) 100 (0–300)
Changes in relative expression of putative chemoresistance genes in tumor-derived cells Figure 3
Changes in relative expression of putative chemoresistance genes in tumor-derived cells. Each dot represents the relative 
mRNA level for an individual sample, measured after in vitro drug exposure compared with untreated control cells. (a) TOPO 
IIα expression in breast (black lines) and ovarian (red lines) tumor cells after doxorubicin exposure. (b) TOPO I expression in 
breast (black lines) and ovarian (red lines) tumor cells after doxorubicin exposure. (c) MRP1 expression in breast (black lines) 
and ovarian (red lines) tumor cells after doxorubicin exposure. (d) TOPO I expression in ovarian tumor cells after topotecan 
exposure. (e) TOPO IIα expression in ovarian tumor cells after topotecan exposure. (f) TS expression in breast (red lines) and 
colorectal (black lines) tumor cells after 5-FU exposure. (g) ERCC1 expression in breast (black lines) and ovarian (red lines) 
tumor cells after cisplatin exposure. (h) TS expression in esophageal tumor cells after ECF exposure. The numerical data for 
these graphs is summarized in Tables 5-8.
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Finally, we looked at EGFR as a marker of tumor growth
and progression. After topotecan exposure we found a
decrease (more than 2-fold) in the expression of this
growth factor in 9/10 ovarian samples (Table 6), with the
median levels decreasing from 0.470 to 0.163 units (p <
0.0039, Wilcoxon).
5-FU effects in short-term cell culture
Preliminary data obtained from 2 esophageal biopsies
indicated an increase of TS levels following 5-FU treat-
ment. Subsequent in vitro experiments performed on
material derived from 10 colorectal tumor samples and 13
breast tumor samples confirmed the expected increase of
TS levels (Table 7) in the samples exposed to 5-FU (p <
0.0001, Wilcoxon; Fig. 3f). The results indicated a general
trend towards DPD down-regulation in the cells that had
been exposed to 5-FU in vitro, though this effect was
modest in most cases and we observed a greater than 2-
fold decrease in only 7/13 breast samples and 2/10 color-
ectal samples.
Cisplatin effects in short-term cell culture
We examined the mRNA expression levels of genes previ-
ously highlighted as important in cisplatin resistance in
tumor-derived cells from 13 breast and 7 ovarian tumors
(Table 8). Up-regulation of the nucleoside excision repair
Table 5: Relative expression of mRNA levels in tumor samples after ex vivo exposure to doxorubicin. The IC50 concentrations for the 
samples tested are shown for each drug (median and range). The p values have been calculated using non-parametric statistics, in 
detail the Wilcoxon matched pairs test. On statistical advice, we chose not to use a Bonferroni's correction, but it should be noted that 
some technically statistically significant results could have arisen by chance.
Breast samples Ovarian samples
Target gene n Control Doxorubicin IC50 = 0.828 µM 
(0.569–1.16)
p n Control Doxorubicin IC50 = 1.34 µM 
(0.310–17.7)
p
BCRP 14 0.039 0.044 0.8077 12 0.010 0.027 0.042
ERCC1 14 0.711 0.826 0.2412 11 0.440 0.506 0.4922
MDR1 14 0.069 0.056 0.0494 12 0.005 0.005 0.2036
MRP1 14 3.886 5.692 <0.0001 12 1.890 2.321 0.083
MVP 14 4.990 6.925 0.0023 12 2.251 2.687 0.042
TOPO I 14 5.464 5.128 0.0419 12 6.112 3.360 0.001
TOPO IIα 14 0.546 0.017 <0.0001 12 1.491 0.089 0.0015
TOPO IIβ 14 6.617 6.461 0.0785 12 5.907 5.252 0.0322
Table 6: Relative expression of mRNA levels in tumor samples after ex vivo exposure to topotecan and irinotecan. The IC50 
concentrations for the samples tested are shown for each drug (median and range). The p values have been calculated using non-
parametric statistics, in detail the Wilcoxon matched pairs test. On statistical advice, we chose not to use a Bonferroni's correction, 
but it should be noted that some technically statistically significant results could have arisen by chance.
Ovarian samples Colorectal samples
Target gene n Control Topotecan IC50 = 0.754 µM 
(0.164–4.82)
p n Control Irinotecan IC50 = 55.4 µM 
(29.5–100)
p
BCRP 9 0.0156 0.0125 >0.999 7 0.0354 0.0515 0.6875
COX-2 10 0.253 0.475 0.7695 7 105.17 38.49 0.0156
EGFR 10 0.470 0.163 0.0039 - - - -
ERCC1 10 0.252 0.399 0.002 7 1.403 2.469 0.0156
MDR1 9 0.0090 0.0034 0.5703 7 0.2253 0.2938 >0.999
MLH1 10 0.263 0.2268 0.0371 - - - -
MRP1 - - - - 7 5.132 3.775 0.0156
TOPO I 10 4.490 2.448 0.0371 7 1.468 1.119 0.1094
TOPO IIα 10 1.093 0.0670 0.002 6 0.2847 0.0733 0.2188
TOPO IIβ - - - - 7 0.7405 0.5058 0.0313BMC Cancer 2005, 5:78 http://www.biomedcentral.com/1471-2407/5/78
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(NER) gene ERCC1 has previously been shown to increase
the removal of platinum affected DNA [22]. We observed
a significant increase in ERCC1 levels in both tumor-
derived breast (p = 0.0266, Wilcoxon matched pairs test)
and ovarian cells (p = 0.0156, Wilcoxon matched pairs
test) (Fig 3g). We also observed significant down regula-
tion of a second DNA repair gene, MSH2 in tumor-derived
breast cells (p = 0.0479, Wilcoxon matched pairs test), but
not in tumor-derived ovarian cells. Samimi et al., [23]
have previously demonstrated that following cisplatin
therapy, there is selection for cells expressing lower
hMLH1 and hMSH2. However, no significant changes
were observed in the other mismatch repair genes, MLH1
and MSH6 in either tumor type (Table 8).
There was no significant change in MGMT in tumor-
derived breast or ovarian cells. However, it has previously
been shown that MGMT mRNA levels begin to recover
after 24 hours in the absence of drug [24]. There was a par-
adoxical decrease in the copper export pump ATP7B fol-
lowing cisplatin exposure (Table 8), in tumor-derived
breast cells (p = 0.0327, Wilcoxon matched pairs test), but
not in ovarian cells. No significant changes were observed
in the heavy-metal binding protein MTII, in either tumor
type.
ECF effects in short-term cell culture
We were able to study tumor-derived cells from 7 esopha-
geal cancer patients, 4 of which had already been given
ECF in vivo. The results mirror those obtained from paired
esophageal biopsies: we noticed increased expression of
TS in the cells that had been exposed to ECF (Fig 3h).
However, the expected up-regulation of MDR1 was only
detected in 4/7 samples (data not shown), and may there-
fore be occurring in non-neoplastic cells that do not nor-
mally express MDR1, rather than in the neoplastic cells,
which we found to express this molecule to the same
degree pre- and post-treatment.
Correlation of in vitro cytotoxicity with molecular 
expression
Lastly, for 5-FU, doxorubicin and irinotecan, IC90 and
IC50 data were obtained by measuring the ATP levels in a
small aliquot of cell suspension at the end of the incuba-
tion period. This allowed a comparison to be made
between drug sensitivity and the expression of putative
Table 7: Relative expression of mRNA levels in tumor samples after ex vivo exposure to 5 FU. The IC50 concentrations for the samples 
tested are shown for each drug (median and range). The p values have been calculated using non-parametric statistics, in detail the 
Wilcoxon matched pairs test. On statistical advice, we chose not to use a Bonferroni's correction, but it should be noted that some 
technically statistically significant results could have arisen by chance.
Breast samples IC50 = 200 µM (86.5–363) Colorectal samples IC50 = 112 µM (13.8–311)
Target gene n Control 5-FU p n Control 5-FU p
DPD 13 1.289 0.494 0.0012 10 0.503 0.448 0.4922
TP 13 8.876 10.928 0.6848 10 4.616 5.963 0.084
TS 13 1.136 3.819 0.0005 10 2.157 7.954 0.002
Table 8: Relative expression of mRNA levels in tumor samples after ex vivo exposure to cisplatin. The IC50 concentrations for the 
samples tested are shown for each drug (median and range). The p values have been calculated using non-parametric statistics, in 
detail the Wilcoxon matched pairs test. On statistical advice, we chose not to use a Bonferroni's correction, but it should be noted that 
some technically statistically significant results could have arisen by chance.
Breast samples IC50 = 18.4 µM (8.9–30.9) Ovarian samples IC50 = 17.8 µM (6.3–25.6)
Target gene n Control Cisplatin p n Control Cisplatin p
ATP7B 13 0.256 0.177 0.0327 7 0.268 0.111 0.4375
ERCC1 13 0.933 1.382 0.0266 7 0.542 0.758 0.0156
MGMT 13 1.203 1.275 0.8926 7 0.794 0.944 0.1094
MLH1 13 0.758 1.000 0.1465 7 0.512 0.683 0.3750
MSH2 13 1.289 1.047 0.0479 7 2.579 2.732 0.9375
MSH6 13 2.351 2.194 0.1909 7 2.997 2.194 0.1094
MTII 13 44.221 53.817 0.5417 7 12.996 11.445 0.8125BMC Cancer 2005, 5:78 http://www.biomedcentral.com/1471-2407/5/78
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resistance genes in the cells that had been exposed to
chemotherapeutic agents. Using multivariate analysis, the
IC90 of 5-FU was correlated with the median change of
mRNA levels of both TS and DPD measured in 5-FU
treated tumor-derived cells compared to control cells
(expressed as 2-∆∆Ct) (R2 = 0.872704; p = 0.0006 for DPD;
p < 0.0001 for TS). In addition, expression of ERCC1
mRNA correlated with the IC50 values determined for
doxorubicin in 11 breast samples (R = 0.7204, p <
0.0124). No other correlations were noted between sensi-
tivity to the drugs and gene expression levels.
Discussion
Our results suggest that rapid adaptation to chemotherapy
may result in a resistant phenotype. This is mediated by
down- or up-regulation of genes that are usually corre-
lated to the mechanism of action of the individual chem-
otherapeutic agent or relevant resistance mechanisms.
Our data suggest that short-term cell culture of tumor-
derived cells with drugs could provide a suitable model
for studying resistance mechanisms. The mechanisms
observed appeared to be more specific to the drug used
than to the tumor type: constitutive resistance probably
reflects pre-chemotherapy expression of resistance mech-
anisms (e.g. drug efflux molecule expression in esopha-
geal carcinoma). Acquired resistance develops rapidly and
is likely to reflect changes in gene regulation rather than
mutation-dependent selection of clones. Clonal selection
may be important in some rapidly growing tumors and
cell lines grown in serum-containing media, but is
unlikely to be the major factor in solid tumors which have
relatively low doubling rates. While mutation-mediated
resistance can be much more profound than that observed
here, our data suggest that the functional effects may still
be sufficient to render the patient's tumor resistant to
treatment within one cycle of chemotherapy.
Changes in resistance and target molecules
A large proportion of the published studies on resistance
to chemotherapy have investigated the development of
resistance using cell lines generated in the lab after pro-
longed and step-wise exposure to anti-cancer drugs. These
in vitro models are not necessarily representative of the in
vivo situation, when patients are usually administered one
cycle of chemotherapy every 3–4 weeks. There are few
studies in clinical samples. Our approach allows us to
expose the tumor cells to single drugs under carefully con-
trolled conditions, even if this would be an inappropriate
drug for that particular patient. We are then able to look
concomitantly at cytotoxicity, and molecular markers of
resistance in the same experiment.
Anthracyclines have a mechanism of action that includes
TOPO IIα inhibition via DNA intercalation. Resistance to
anthracyclines is thought to be mediated by a number of
different mechanisms, which include mutation or altera-
tion of its target enzyme, TOPO IIα, and up-regulation of
drug efflux proteins, such as BCRP, MRP1, MVP and MDR-
1 [25]. Our data show that many of the cell line data are
correct: in most solid tumors, it appears that anthracycline
and topotecan exposure do lead to decreased topoisomer-
ase II and I expression respectively, while inducing the
expression of drug efflux pump molecules. The reason for
the alteration in topoisomerase II expression following
topotecan exposure is not clear, but topotecan does affect
cell proliferation, and any reduction in proliferation
would indirectly affect the expression of topoisomerase II
alpha induced during S phase. However, our results also
suggest that the heterogeneity of chemosensitivity
between tumors is reflected by heterogeneity of molecular
determinants of resistance/sensitivity.
The increased TS levels in ECF and 5-FU exposed cells is
consistent with a number of previous reports. Gene
amplification of TS with consequent increases in TS
mRNA and protein has been observed in cell lines that are
resistant to 5-FU and fluorodeoxyuridine (FUDR) [26,27].
Treatment with 5-FU has been shown to acutely induce TS
expression in cell lines, animal models and human
tumors [19,28-30]. In general there is strong evidence that
the expression of DPD and TS in GI cancers is predictive
of response to 5-FU. It should be noted that the concom-
itant measurement of both these markers markedly
enhanced the ability to predict tumor response to 5-FU-
based chemotherapy in a number of studies [31-34].
Gene profiling and drug response
There are few studies comparing gene expression before
and after chemotherapy. A few studies have reported
microarray data in biopsy material taken before and after
(or even during) chemotherapy. These studies are of great
interest, though normal cell effects cannot be excluded
from the results. Buchholz et al. [35] employed cDNA
microarray to measure gene expression changes during
chemotherapy in 5 patients with breast cancer. Clarke et
al. [36] studied gene expression changes in 18 rectal can-
cer patients undergoing therapy with Mitomycin C or 5-
FU. This study reported a number of genes implicated in
protein synthesis and RNA metabolism to be significantly
decreased during drug treatment. These studies are not
directly comparable: tumors of different types respond
better to different drugs, and differences in their adapta-
tion to these drugs are therefore expected on the basis of
their innate sensitivity or resistance.
The potential for positive selection: molecular chess
It is common to show a cross-over effect with clinical trials
of treatments with differing mechanisms of action, in
which patients treated with one type of chemotherapy
show sensitivity to the alternative regimen following fail-BMC Cancer 2005, 5:78 http://www.biomedcentral.com/1471-2407/5/78
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ure of the one to which they were allocated. The recogni-
tion that selection of a molecular phenotype by exposure
to one anti-cancer agent may leads to the expression of
molecular targets for other drugs raises the possibility that
it might be possible to enhance sensitivity to second-line
or maintenance therapy by careful selection of patients for
first-line therapy [37]. This approach would provide
patients with a "backstop" for their first-line chemother-
apy. One can envisage a series of interlocking treatments
using drugs with specific molecular targets, monitored by
molecular assays, which would allow the oncologist to
employ a form of molecular chess to defeat the tumor.
This approach might overcome the inherent heterogene-
ity, which is likely to underlie the variable results obtained
from sequential chemotherapy to date. Assessment of this
process in tumors could provide predictive assays allow-
ing the oncologist to tailor therapy to the patient and
avoid the development of resistance within the tumor.
Conclusion
In summary, this study suggests that up-regulation of
resistance genes or down-regulation in target genes may
occur rapidly in human solid tumors, within days of the
start of treatment, and that similar changes are present in
pre- and post-chemotherapy biopsy material. The molec-
ular processes used by each tumor appear to be linked to
the drug used, but there is heterogeneity between
individual tumors, even those with the same histological
type, in the pattern and magnitude of response to the
same drugs. Adaptation to chemotherapy may explain
why prediction of resistance mechanisms is difficult on
the basis of tumor type alone or individual markers, and
suggests that more complex predictive methods are
required to improve the response rates to chemotherapy.
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